Medical/Pharmaceuticals

Bringing K-Aesthetics to Australia: PharmaResearch Showcases REJURAN® at Aesthetics 2026

Following REJURAN®'s TGA approval in 2023, the company hosted scientific sessions and a clinical masterclass for Australian healthcare professionals. GANGNEUNG, South Korea, Aug. 13, 2026 /PRNewswire/ -- PharmaResearch, the biopharmaceutical company behind REJURAN®, recently participated in Aesth...

2026-08-13 08:00 4225

VITAMIN ANGELS EXPANDS PARTNERSHIP WITH THE MINISTRY OF HEALTH OF INDONESIA TO STRENGTHEN NATIONWIDE VITAMIN A CAMPAIGN

Collaboration strengthened health worker training, communication strategies, monitoring and evaluation, and delivered 870,000 vitamin A capsules for children across Indonesia. Vitamin A can reduce child mortality by up to 24% among children ages 6 to 59 months in populations at risk of vitamin A...

2026-08-13 03:45 4602

Osara Health Marks 10 Years with Global Call to Make Cancer Support Beyond Treatment Standard

Launched to mark the company's 10th anniversary, Osara Health's Global Cancer Support Declaration has already secured signatures from healthcare professionals worldwide. NEW YORK, Aug. 12, 2026 /PRNewswire/ -- Osara Health, a global digital health company focused on the human experience of cance...

2026-08-12 23:17 3067

PanTRKare™ Officially Approved as the Companion Diagnostic for VELMARTO® (Eratrectinib)

NANJING, China, Aug. 12, 2026 /PRNewswire/ -- August 6, the NMPA granted approval to Geneseeq's PanTRKare™ NTRK1/2/3 Gene Fusion Detection Kit as a companion diagnostic for VELMARTO® (Eratrectinib), a next‑generation highly selective TRK inhibitor independently developed by Vcare PharmaTech. The ...

2026-08-12 22:00 2982

RingConn Advances Wearable Health Research with New Study in Nature Portfolio Journal npj Digital Medicine

The study, "Large-scale bilateral cardiovascular monitoring via wearable rings," analyzes 97,559 valid ring-PPG samples from 1,810 participants, providing new insights into bilateral wearable sensing for cardiovascular monitoring. NEW YORK, Aug. 12, 2026 /PRNewswire/ -- A major step toward overc...

2026-08-12 22:00 4238

Insilico Medicine Nominates ISM0900, a Potent, AI-driven, Oral Lp(a) Inhibitor, as PCC for Management of Cardiovascular Risks

CAMBRIDGE, Mass., Aug. 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the nomination of ISM0900, a potent, AI-driven, highly selective, orally available small molecule inh...

2026-08-12 20:30 2081

Beyang Closes Oversubscribed $30 Million Series A Financing

Funding to accelerate the iteration of the proprietary AI-driven ExCEED platform and advance global clinical development of differentiated pipelines, including a second-generation Menin inhibitor and a novel ophthalmic therapy. CHENGDU, China, Aug. 12, 2026 /PRNewswire/ -- Beyang Therapeutics Co....

2026-08-12 17:38 2898

Beyang Closes Oversubscribed $30 Million Series A Financing

Funding to accelerate the iteration of the proprietary AI-driven ExCEED platform and advance global clinical development of differentiated pipelines, including a second-generation Menin inhibitor and a novel ophthalmic therapy. CHENGDU, China, Aug. 12, 2026 /PRNewswire/ -- Beyang Therapeutics Co....

2026-08-12 17:10 2928

Introducing Oticon Reveal™ - the world's first hearing aid powered by Dual AI

From only words to a richer world of sound SMØRUM, Denmark, Aug. 12, 2026 /PRNewswire/ -- Today, Oticon launches Oticon Reveal™, the world's first hearing aid powered by Dual AI, delivering crystal-clear speech and meaningful sounds in optimal balance, bringing hearing aid users closer to a natu...

2026-08-12 14:00 2944

New Drug Application for LAE002 (afuresertib) Accepted by China's National Medical Products Administration

SHANGHAI, Aug. 11, 2026 /PRNewswire/ -- Laekna (2105.HK) announced today that the New Drug Application (NDA) for LAE002 (afuresertib) has been accepted by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the treatment of patients with locally adv...

2026-08-12 08:45 2267

Datasea Announces FDA Registration and Device Listing for NeuroVibe Acoustic BCI Biofeedback System as a Class II 510(k)-Exempt Biofeedback Medical Device

BEIJING, Aug. 11, 2026 /PRNewswire/ -- Datasea Intelligent Technology Ltd. (NASDAQ: DTSS) ("Datasea" or the "Company"), a technology company focused on acoustic high-tech and AI multimodal digital solutions, today announced that Shuhai Jingwei (Shenzhen) Information Technology Co., Ltd. ("Shuhai ...

2026-08-11 21:01 2325

Metabolon Launches Peak Science Grant Program to Advance Breakthrough Metabolomics Research

Quarterly grant program provides researchers with no-cost access to Metabolon's industry-leading metabolomics platform, scientific expertise, bioinformatics tools, and data interpretation resources MORRISVILLE, N.C., Aug. 11, 2026 /PRNewswire/ -- Metabolon, Inc., the global leader in metabolomic...

2026-08-11 21:00 1720

Bracco Marks Major Global Milestone with U.S. FDA 510(k) Clearance and Health Canada Authorization for VueJect®, the First Dedicated Ultrasound Contrast Delivery System to Support Cardiology Imaging

VueJect® strengthens Bracco's integrated CEUS ecosystem by enabling more standardized, efficient contrast administration in cardiology imaging MILAN, Aug. 11, 2026 /PRNewswire/ -- Bracco Imaging today announced that VueJect®, its first dedicated ultrasound contrast delivery system engineered to ...

2026-08-11 20:00 1850

Korean Biotech Company K-Medichem Expands Global Market Reach with PDRN Derma Skincare Line in Vietnam, Indonesia and Beyond

* PDRN Derma cream, serum, and mask lineup positions premium K-dermocosmetics based on patented ingredients for Southeast Asian market expansion CHUNCHEON, South Korea, Aug. 11, 2026 /PRNewswire/ -- K-Medichem Co., Ltd. (K-Medichem), a Korean biotech company built on university research, is acc...

2026-08-11 19:17 3003

Cambrex Milan Celebrates 80th Anniversary with Construction of New $30 Million R&D Facility

EAST RUTHERFORD, N.J., Aug. 11, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced the start of construction on a new research and development (R&D) facility at its Milan, Italy site. This $30 million investment will add adva...

2026-08-11 18:00 2185

Insilico Medicine Announces 2026 Interim Earnings Conference Call Dates

CAMBRIDGE, Mass., Aug. 11, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that it will hold conference calls to discuss its financial results for the six months ended June 30,...

2026-08-11 17:45 2029

Haleon and Singapore's Agency for Science, Technology and Research (A*STAR) Launch New Clinical Study on Women's Metabolic Health in Asia

* A new clinical study on the multivitamin and mineral supplement Centrum is designed to generate evidence on metabolic health in midlife Asian women - a group often underrepresented in global nutrition research. * The study will contribute to a better understanding of preventive healthcare a...

2026-08-11 11:41 2183

Global Study Results Published in Aesthetic Surgery Journal Open Forum Show Link Between Self-Confidence and Aesthetics

Publication in the peer-reviewed journal reinforces the study's insights and validates what clinicians frequently observe – that the impact of aesthetic treatments extends beyond physical appearance.  * The Pillars of Confidence Global Study, supported by Merz Aesthetics, evaluated the impact ...

2026-08-11 10:00 1895

Aureka Biotechnologies Raises US$100 Million Series B to Build a Biological World Model for Drug Discovery

LAGUNA HILLS, Calif. and SHANGHAI, Aug. 10, 2026 /PRNewswire/ -- Aureka Biotechnologies announced the close of a US$100 million Series B financing on Aug. 10, 2026. Granite Asia funded the first tranche exclusively, and a prominent strategic investor led a subsequent tranche, with participation f...

2026-08-11 09:30 3282

Lifespan Vision Ventures Leads Remedium Bio's Series A Financing

Investment supports advancement of Remedium's durable protein therapeutics platform toward first-in-human clinical development. NORWALK, Conn., Aug. 10, 2026 /PRNewswire/ -- Lifespan Vision Ventures today announced that it is leading Remedium Bio, Inc.'s ("Remedium") $10 million Series A financi...

2026-08-10 22:00 2544
1 ... 45678910 ... 645